References
- Gibbons, R. D., and A. Amatya. 2015. Statistical methods for drug safety. London, UK: Chapman and Hall.
- Hedeker, D., and R. D. Gibbons. 2006. Longitudinal data analysis. New York, NY: Wiley.
- Johnston, D. I., A. Chang, M. Viray, K. Chatham-Stephens, H. He, E. Taylor, L. L. Wong, J. Schier, C. Martin, D. Fabricant, M. Salter, L. Lewis, and S. Y. Park. 2016. Hepatotoxicity associated with the dietary supplement OxyELITE Pro™ — Hawaii, 2013. Drug Testing and Analysis 8:319–327. doi:10.1002/dta.1894.
- Klontz, K. C., H. J. DeBeck, P. LeBlanc, K. M. Mogen, B. J. Wolpert, J. L. Sabo, M. Salter, S. L. Seelman, S. E. Lance, C. Monahan, D. S. Steigman, and K. Gensheimer. 2015. The role of adverse event reporting in the FDA response to a multistate outbreak of liver disease associated with a dietary supplement. Public Health Reports 130 (5):526–32. doi:10.1177/003335491513000515.
- Park, S. Y., M. Viray, and D. Johnston. 2013. Note from the field: Acute hepatitis and liver failure following the use of dietary supplement intended for weight loss or muscle building. Morbidity and Mortality Weekly Report 62 (40):817–19.
- Roytman, M. M., P. Porzgen, C. L. Lee, L. Huddleston, T. T. Kuo, P. Bryant-Greenwood, L. L. Wong, and N. Tsai. 2014. Outbreak of severe hepatitis linked to weight-loss supplement OxyELITE Pro. American Journal of Gastroenterology 109 (8):1296–98. doi:10.1038/ajg.2014.159.